Arjunolic acid

Arjunolic Acid

1. Identity: Chemical and Botanical Profile

Arjunolic acid (AA) is formally named 2,3,23-trihydroxyolean-12-en-28-oic acid, and it is a chiral pentacyclic triterpenoid saponin isolated from Terminalia arjuna (Roxb.) Wight & Arn., a member of the family Combretaceae. Its molecular formula is C₃₀H₄₈O₅, and it is registered in PubChem under CID 73641. The compound carries CAS registry number 465-00-9. Synonyms appearing in the chemical literature include arjulic acid and, by its full IUPAC name, (2α,3β,4α)-2,3,23-trihydroxyolean-12-en-28-oic acid. Its molecular weight is 460.7 g/mol.

Arjunolic acid is a pentacyclic triterpenoid first isolated from the tropical hardwood Terminalia arjuna, and its structure was resolved by researchers at the University of Nottingham, UK. Subsequently, arjunolic acid was found in a diverse range of hardwood species. It is a triterpenoid saponin, isolated earlier from Terminalia arjuna and later from Combretum species and other plants. Additional source plants identified in the literature include Combretum nelsonii and Leandra chaeton. A 2025 study confirmed its presence and significant bioactivity in the stem bark of Terminalia ivorensis A. Chev., collected in the Centre Region of Cameroon.

Terminalia arjuna tree bark accumulates highly oxygenated β-amyrin-derived oleanane triterpenoids — including arjunic acid, arjungenin, and arjunolic acid — that have been credited with cardioprotective roles. Within the bark, arjunolic acid belongs to the oleanane-type triterpene subclass. It is characterized by diverse biological functions including antidiabetic, antifungal, antibacterial, antitumor, antiasthmatic, and wound healing properties.

Common Forms and Preparations

The bark extract of T. arjuna contains arjunolic acid as one of three triterpene saponins — alongside arjunic acid and arjungenin — and also triterpene glycosides (arjunetin, arjunoglucoside I/II/III, arjunoside I/II/III/IV), flavonoids, phytosterols, proanthocyanidins, and minerals. In traditional and modern preparations, the compound is encountered primarily as:

• Bark powder: dried and powdered bark of T. arjuna, the most historically widespread form.
• Bark decoction (aqueous extract): bark boiled in water or milk, a classical Ayurvedic preparation.
• Standardized bark extracts: concentrated preparations used in dietary supplements, typically standardized to triterpenoid content.
• Isolated pure compound: used in laboratory and preclinical research, typically obtained at ≥95% purity by LC/MS-ELSD.

2. Traditional and Historical Use

Terminalia arjuna is a widely used herbal plant since ancient times; ancient Indian practitioners utilized the powdered tree bark for the treatment of "hritshool" (angina) and other cardiovascular problems. References to Terminalia arjuna date back over two millennia; the Charaka Samhita (1st–2nd century CE) mentions "Marudah" bark for balancing Vata and soothing the cardiac region. In the Sushruta Samhita, physicians praised Arjuna's bark decoction for stopping bleeding and accelerating healing of wounds, indicating its use was not limited to cardiac applications but extended to topical wound management.

Chakradatta, a noted ancient physician, recommended arjuna be given as a decoction of bark with milk or as a ghrita (a preparation with ghee or butter). Traditionally, the plant is used in the treatment of cardiovascular disease, referred to in classical Ayurveda as hridya roga.

Terminalia arjuna, regionally called arjuna, belongs to the Combretaceae family and is utilized as medicine in various indigenous systems including Ayurveda, Siddha, and Unani. Traditional Siddha practitioners in South India employed decoctions of arjuna bark to fight infections, while Unani healers used its extracts for dropsy (edema).

Terminalia arjuna is popularly known as the "tonic of the heart" plant due to its high utility in treating the heart since ancient times. Traditionally, the bark has also been applied to wounds for its astringent and healing properties, and is classically regarded as a bone-healing (sandhaneeya) herb that may support the recovery of fractures.

3. Phytochemical Context and Key Active Constituents of the Source Plant

Arjunolic acid is one constituent in a complex phytochemical matrix. The major phytoconstituents of Terminalia arjuna include arjunic acid, arjunolic acid, arjungenin, arjunone, arjunolone, luteolin, gallic acid, ellagic acid, oligomeric proanthocyanidins (OPCs), and phytosterols, which collectively contribute to its antimicrobial, anti-inflammatory, antioxidant, and cardioprotective properties. The oleanane triterpenoids detected in the bark in the forms of sapogenins (arjunic acid, arjunolic acid, and arjungenin) and saponins (arjunetin, arjunglucoside I and II) contribute to major bioactivities, such as cardioprotective, antioxidant, anti-inflammatory, and hypocholesterolemic activities.

Isolated from ethanolic bark extract, oleanane triterpenoid-type compounds including oleanolic acid, arjunolic acid, arjunolitin, and arjunetin have had their structures elucidated by ¹H, ¹³C NMR, HR-ESIMS, and IR spectroscopy.

4. Established Mechanisms of Action

Research has attributed arjunolic acid's wide range of biological effects to several converging molecular mechanisms. The compound acts on multiple pathways simultaneously, reflecting its polypharmacological character.

4.1 Antioxidant and Free Radical Scavenging Activity

The mechanism of cytoprotection conferred by arjunolic acid can be explained by its property to reduce oxidative stress by enhancing antioxidant levels. Its antioxidant property, coupled with a metal-chelating property conferred by its two hydroxyl groups, protects different organs from metal- and drug-induced organ pathophysiology. This compound is renowned for its potent ability to scavenge free radicals and chelate metal ions, mechanisms that are crucial in mitigating oxidative stress within biological systems. It scavenges DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals in a cell-free assay when used at a concentration of 0.8 mM.

Arjunolic acid treatment has been shown to prevent the decrease in the levels of superoxide dismutase, catalase, glutathione peroxidase, ceruloplasmin, α-tocopherol, reduced glutathione (GSH), ascorbic acid, and related antioxidant indices in cardiac disease models.

4.2 PPARα Agonism and Cardiac Fibrosis Regression

Arjunolic acid binds to and stabilizes the ligand-binding domain of peroxisome proliferator-activated receptor α (PPARα) and increases its expression during cardiac hypertrophy. The compound significantly represses collagen expression and improves cardiac function during hypertrophy. In a further study, cardiac fibrosis was reversed by AA by inhibiting non-canonical transforming growth factor (TGF)-β signaling; inhibition of TGF-β-activated kinase 1 (TAK1) phosphorylation leads to reduction of p38 mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) p65 activation.

4.3 Inhibition of ROS Production and Mitochondrial Protection

Arjunolic acid improved myocardial infarction by inhibiting reactive oxygen species (ROS) generation; research demonstrated decreased levels of p47(phox)-serine phosphorylation and mitochondrial dysfunction upon treatment.

4.4 Anti-inflammatory Signaling

AA has shown promise against type 1 diabetes through its prevention of hyperglycemia-induced activation of MAPKs, PKC, and NF-κB signaling cascades. The inhibition of NF-κB pathway components represents a shared mechanism across its cardioprotective, hepatoprotective, and antidiabetic activities.

4.5 Antiplatelet and Anticoagulant Effects

Purified arjunolic acid has produced anti-oxidant, anti-platelet, anti-coagulant, anti-necrotic, anti-apoptotic, free radical-scavenging, anti-inflammatory, hypolipidemic, and hypotensive effects in various cardiac disease models. Experiments in rats administered arjunolic acid extracted from T. arjuna demonstrated an antiplatelet and anticoagulant action similar to that of acetylsalicylic acid.

4.6 Apoptosis Modulation

In studies of doxorubicin-induced cardiac toxicity, rats treated with doxorubicin displayed elevated apoptotic indices in heart tissue, whereas arjunolic acid treatment effectively neutralized these doxorubicin-induced cardiac abnormalities; results suggest that doxorubicin induces cardiac apoptosis via activation of JNK-p38 and p53-mediated signaling pathways, and that arjunolic acid can counteract this action and may potentially protect the heart and cardiomyocytes from doxorubicin-induced cardiovascular burden.

5. Scientific Evidence by Area of Use

Important framing note: The overwhelming majority of published research on arjunolic acid is preclinical in nature — conducted in cell cultures (in vitro) or in animal models (in vivo), predominantly rodents. Experimental studies demonstrate versatile effects of arjunolic acid, but further investigations are necessary to identify the functional groups responsible for its multivarious effects and to study the molecular mechanisms as well as the probable side effects and toxicity owing to its long-term use. No large-scale randomized controlled trials in humans for isolated arjunolic acid have been identified in the peer-reviewed literature as of the time of writing. Evidence strength for each area is characterized accordingly.

5.1 Cardiovascular Protection

Evidence level: Preclinical (animal models and cell lines); no human RCTs for isolated compound.

The scientific basis behind its therapeutic application as a cardioprotective agent in traditional medicine is justified by its ability to prevent myocardial necrosis and apoptosis, platelet aggregation, and coagulation, and to lower blood pressure, heart rate, and cholesterol levels. In 2001, Sumitra et al. reported the antioxidant features of arjunolic acid, as well as cardioprotective effects in lowering platelet aggregation and coagulation parameters in rats with isoproterenol-induced myocardial necrosis.

Bansal et al. (2017, published in Journal of Biological Chemistry) investigated the mode of action of arjunolic acid in ameliorating hemodynamic load-induced cardiac fibrosis; their data revealed that AA significantly represses collagen expression and improves cardiac function during hypertrophy, and that it binds to and stabilizes the ligand-binding domain of PPARα, increasing its expression during cardiac hypertrophy.

AA has been reported to possess a cardioprotective effect through different mechanisms. An aqueous extract of arjuna bark containing arjunolic acid significantly inhibited isoprenaline-induced increase in oxidative stress and also prevented fibrosis, though without regression of hypertrophy or improvement of cardiac function. Human clinical evidence for isolated arjunolic acid specifically (as distinct from whole T. arjuna bark preparations) is absent from the current published record.

5.2 Diabetes and Metabolic Protection

Evidence level: Preclinical only; predominantly rodent models.

Arjunolic acid plays an effective role in exerting protection against both type 1 and type 2 diabetes and also ameliorates diabetic renal dysfunctions. The compound plays a beneficial role in the pathogenesis of diabetes and its associated complications.

The anti-diabetic mechanism involves prevention of hyperglycemia-induced activation of MAPK, PKC, and NF-κB signaling cascades. A 2012 review by Manna and Sil in Free Radical Research (PMID 22486656) comprehensively documented arjunolic acid's beneficial role specifically in type 1 diabetes and its associated organ pathophysiology, covering rodent studies involving streptozotocin-induced diabetic models. One such study, published in Free Radical Biology and Medicine (2010), documented the contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IκBα/NF-κB, MAPKs, and mitochondria-dependent pathways, along with the prophylactic role of arjunolic acid. No human intervention trials using isolated arjunolic acid for diabetes management have been published.

5.3 Hepatoprotection

Evidence level: Preclinical (cell lines and rodent models); no human trials.

Arjunolic acid has been found to be beneficial in protecting against acetaminophen (APAP)-induced liver and hepatocyte injury. Research has investigated the cytoprotective role of arjunolic acid against cadmium-induced oxidative impairment and cell death in murine hepatocytes. Arjunolic acid exhibits antioxidant, anti-inflammatory, and free radical scavenging activities relevant to liver protection. One earlier study by Manna and Sil (2007, Basic & Clinical Pharmacology & Toxicology) investigated arjunolic acid against arsenic-induced hepatic oxidative damage in mice, finding dose-dependent protective effects; however, this study was subsequently retracted, with a retraction notice published in Basic & Clinical Pharmacology & Toxicology in 2025. Evidence from non-retracted cell-culture and rodent studies continues to support hepatoprotective potential, but no human clinical confirmation exists for the isolated compound.

5.4 Nephroprotection (Kidney Protection)

Evidence level: Preclinical only.

Arjunolic acid has been studied as a potential natural therapy against nephrotoxicity in preclinical models. Its nephroprotective effects have been demonstrated in streptozotocin-induced diabetic rodent models where diabetic renal dysfunction was ameliorated. Post-treatment with arjunolic acid at a dose of 20 mg/kg body weight for four days reduced atorvastatin-induced oxidative stress and suppressed apoptotic events, with results suggesting that arjunolic acid could effectively counteract adverse effects and might protect liver and kidney from severe tissue toxicity. No human studies have evaluated arjunolic acid specifically for kidney protection.

5.5 Neuroprotection

Evidence level: Preclinical only (murine models).

A 2008 study in the Journal of Biochemical and Molecular Toxicology (Sinha, Manna, and Sil) was designed to investigate the preventive role of arjunolic acid against arsenic-induced oxidative damage in murine brain; the compound's free-radical-scavenging activity and in vivo antioxidant power were determined using DPPH radical scavenging ability and ferric reducing/antioxidant power assays. Arjunolic acid administered at 20 mg/kg for four days prevented arsenic-induced decreases in the activity of superoxide dismutase (SOD1), catalase, GST, and glutathione reductase in mouse brain. Arjunolic acid has been studied as a potential natural therapy against oxidative damage associated with cerebral ischemia in preclinical settings.

5.6 Anticancer Properties

Evidence level: Primarily in vitro and early in vivo; no human clinical trials.

Arjunolic acid is a pentacyclic triterpenoid with promising anticancer properties. Ehrlich ascites carcinoma (EAC) and Dalton's lymphoma (DAL) cell lines were incubated with different concentrations of arjunolic acid; results showed that a 100 µg concentration induced approximately 66% cell death in DAL cells and 70% in EAC cells, primarily through membrane disruption. Arjunolic acid also exhibited significant anticancer activities against MCF-7 and HeLa cell lines, with minimal toxicity observed in normal lymphocytes. Fluorescence-based analyses showed that arjunolic acid at 50 µg/mL disrupts redox balance in cancer cells by generating reactive oxygen species.

A 2025 study published in Cancer Reports (PMC12411669) tested arjunolic acid isolated from Terminalia ivorensis against breast cancer. The crude extract and five isolates were subjected to in vitro MTT bioassay against human MCF-7, MDA-MB-231, and murine 4T1 breast cancer cell lines; the most active compound, arjunolic acid, was further tested for its potential to mitigate DMBA-induced breast cancer in rats. In vivo, a significant reduction (approximately 89%) in tumor burden was observed, with favorable modulation of inflammation characterized by a decrease in pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, VEGF) and an increase in anti-inflammatory IL-10; treatment with arjunolic acid led to improved survival and maintenance of body weight, without inducing any notable adverse effects.

In the field of derivative chemistry, a series of novel arjunolic acid derivatives containing a pentameric A-ring with an enal moiety, combined with additional modifications at C-28, were designed and prepared, with biological activity on viability of human cancer and non-tumor cell lines evaluated; the most active derivative (compound 26) showed the best selectivity between malignant cells and non-malignant fibroblasts and induced cell-cycle arrest at G0/G1 phase, significantly inhibiting wound closure rate of PANC-1 cancer cells in a concentration-dependent manner.

5.7 Antimicrobial and Antifungal Effects

Evidence level: In vitro and whole-extract studies; no human clinical trials for isolated compound.

Arjuna bark showed significant inhibition zones against 22 tested bacteria, including eight uropathogens, with minimum inhibitory concentration (MIC) values between 0.16 and 2.56 mg/mL; the chloroform extract showed no antibacterial activity. The aqueous extract demonstrated strong antifungal effects against eight Candida species, with MIC values ranging from 0.16 to 0.64 mg/mL. Aqueous extracts of Terminalia arjuna (fruit, bark, root, and leaves) demonstrated notable antibacterial properties, with the bark extract effectively inhibiting growth of both Gram-positive and Gram-negative bacteria. Most of these findings pertain to whole extracts rather than isolated arjunolic acid specifically.

5.8 Protection Against Drug- and Chemical-Induced Organ Toxicity

Evidence level: Preclinical only.

A significant body of research by Parames C. Sil and colleagues at Bose Institute (Kolkata) has focused on arjunolic acid as a cytoprotective agent against diverse toxic insults. Arjunolic acid has been investigated for its cytoprotective role against cadmium-induced oxidative impairment and cell death in murine hepatocytes; cadmium administration significantly enhanced ALT, ALP, and LDH leakage, increased ROS production, and altered antioxidant status. Post-treatment with arjunolic acid at a dose of 20 mg/kg body weight for four days reduced atorvastatin-induced oxidative stress and suppressed apoptotic events in both liver and kidney, suggesting that the compound could protect these organs from atorvastatin-induced severe tissue toxicity.

6. Body Systems and Health Areas

Arjunolic acid has been studied as a potential natural therapy against cardiac fibrosis, non-alcoholic fatty liver disease, nephrotoxicity, diabetes, and oxidative damage associated with cerebral ischemia. The following body systems have been specifically implicated in the research record:

• Cardiovascular system: AA has been reported to possess a cardioprotective effect through different mechanisms, including anti-fibrotic, antioxidant, antiplatelet, antihypertensive, and anti-apoptotic activity in the heart muscle.
• Hepatic system: The specific and non-specific phytocompounds of T. arjuna bark, including arjunolic acid, are known to confer hepatoprotective effects.
• Renal system: Arjunolic acid plays an effective role in protection against both type 1 and type 2 diabetes and also ameliorates diabetic renal dysfunctions.
• Endocrine/metabolic system: The compound acts on MAPK, PKC, and NF-κB cascades implicated in insulin signaling and hyperglycemic damage.
• Nervous system: Preclinical evidence indicates neuroprotective effects against chemical oxidative stressors in murine brain tissue.
• Immune/inflammatory pathways: Arjunolic acid exhibits antioxidant, anti-inflammatory, and free radical scavenging activities relevant to immune modulation.
• Oncology (experimental): In vitro and early in vivo data demonstrate activity against multiple cancer cell lines through ROS-mediated apoptosis and cell cycle arrest.

7. Dosages Reported in Preclinical Studies

Because no established human clinical dosage for isolated arjunolic acid has been determined, the following dosages are drawn exclusively from preclinical animal studies as stated in the primary sources and are not extrapolatable to human use without further clinical validation.

• Arjunolic acid was administered at a dose of 20 mg/kg body weight for 4 days prior to arsenic administration in murine hepatotoxicity studies.
• Post-treatment with arjunolic acid at a dose of 20 mg/kg body weight for 4 days reduced atorvastatin-induced oxidative stress and suppressed apoptotic events in liver and kidney studies.
• In the acute oral toxicity study, arjunolic acid was administered orally at individual doses of 300 mg/kg and 2000 mg/kg body weight in female Sprague-Dawley rats.
• In cardiac disease models using isoproterenol-induced myocardial necrosis, arjunolic acid was tested at doses previously compared directly against acetylsalicylic acid (ASA) as a reference cardioprotective drug.

8. Safety Considerations

8.1 Preclinical Acute Toxicity

Arjunolic acid is a potent phytochemical with wide pharmacological activities; despite its potential medicinal properties across various in vitro and in vivo studies, there is a dearth of scientific data related to its safety profile and toxicological parameters. In an acute oral toxicity study, arjunolic acid was administered at individual doses of 300 mg/kg and 2000 mg/kg body weight in female Sprague-Dawley rats, with all animals observed for two weeks to determine behavioral and physical changes. Results showed no morbidity and mortality at either dosage; daily food and water intake, body weight, relative organ weight, hematological and biochemical parameters were detected to be normal, with no severe alteration seen through microscopical investigation of harvested tissues, supporting the safety profile of arjunolic acid and indicating it was well tolerated at the higher dose; the authors noted that an in-detail study on the subacute disease model is still warranted.

8.2 Adverse Effects of Whole T. arjuna Preparations

Arjuna bark preparations are usually well tolerated; however, mild adverse effects including headache, nausea, gastritis, constipation, and sleeping disorders were seen in a few cases, and these adverse effects are usually associated with increased dosage. Long-term use of arjuna preparations (up to 24 months) has been reported to be safe without significant hematological, hepatic, renal, or metabolic toxicity in at least one study.

8.3 Potential Drug Interactions

Arjunolic acid extracted from T. arjuna demonstrated antiplatelet and anticoagulant action similar to that of acetylsalicylic acid in rat experiments. This preclinical anticoagulant activity raises theoretical concerns about additive effects with anticoagulant or antiplatelet pharmaceutical agents, though this interaction has not been systematically evaluated in human studies. In dogs, T. arjuna bark extract caused dose-dependent hypotension, suggesting adrenergic beta-2 receptor agonist activity, which could theoretically be relevant in the context of antihypertensive drug use.

8.4 Retraction of Key Study

Researchers should be aware that at least one widely cited preclinical paper — the 2007 study by Manna et al. in Basic & Clinical Pharmacology & Toxicology on arjunolic acid against arsenic-induced hepatic disorder — was formally retracted, with a retraction notice published in Basic & Clinical Pharmacology & Toxicology in 2025 (doi: 10.1111/bcpt.70113). This retraction should be factored into any assessment of the hepatoprotective evidence base.

8.5 Gaps in the Safety Profile

The versatile effects of arjunolic acid have been demonstrated in experimental studies, but further investigations are necessary to study the molecular mechanisms as well as the probable side effects and toxicity owing to its long-term use. Although arjunolic acid has multiple pharmacological activities, the scientific data on its toxicological and safety profile in animals remain to be fully elucidated. No formal pharmacokinetic studies in humans, no established no-observed-adverse-effect levels (NOAELs) in standard regulatory toxicology formats, and no human bioavailability data for the isolated compound have been published in peer-reviewed sources identified in this review.

9. Research Landscape and Evidence Limitations

Arjunolic acid represents a novel phytomedicine with multifunctional therapeutic applications, with research covering its isolation from both Terminalia arjuna and other Combretum species. The compound has attracted considerable scientific interest, particularly in South Asian and international phytochemistry research groups.

Several limitations constrain the translation of existing evidence to clinical recommendations:

• The research base is almost entirely preclinical; no Phase I, II, or III human clinical trials using isolated arjunolic acid as an intervention have been published.
• Most in vivo studies use rodent models and administered the compound by injection or gavage, which may not reflect oral bioavailability in humans.
• The retraction of at least one major study in the hepatoprotection area weakens the preclinical evidence base for that application.
• The precise molecular mechanism of cardioprotection by arjunolic acid has still remained elusive, and its pleiotropic effects make it difficult to annotate specific molecular targets within the cellular milieu.
• Human pharmacokinetic data (absorption, distribution, metabolism, excretion) for arjunolic acid are not yet available in the open literature.

References

• PubChem — Arjunolic Acid | C30H48O5 | CID 73641 (NIH)
• Hemalatha T et al. Arjunolic acid: a novel phytomedicine with multifunctional therapeutic applications. Indian J Exp Biol. 2010 Mar;48(3):238-47. PMID: 21046976
• Ghosh J, Sil PC. Arjunolic acid: a new multifunctional therapeutic promise of alternative medicine. Food Chem Toxicol. 2013 May;55:688-98. PMID: 23402784
• Manna P, Sil PC. Arjunolic acid: beneficial role in type 1 diabetes and its associated organ pathophysiology. Free Radic Res. 2012 Sep;46(7):815-30. PMID: 22486656
• Bansal T et al. Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling. J Biol Chem. 2017;292:16440. PMC5633106
• Cardioprotective effects of arjunolic acid in LPS-stimulated H9C2 and C2C12 myotubes via the MyD88-dependent TLR4 signaling pathway. PMC10375937
• Gonçalves BMF et al. Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents. RSC Med Chem. 2023;14(2):313-331. PMC9945870
• Akamse MA et al. Arjunolic Acid From Terminalia ivorensis A. Chev (Combretaceae) Possesses Anti-Breast Cancer Effects In Vitro and In Vivo. Cancer Reports. 2025. PMC12411669
• Oral toxicity of arjunolic acid on hematological, biochemical and histopathological investigations in female Sprague Dawley rats. PeerJ. 2019. PMC6876537
• Protective effect of arjunolic acid against atorvastatin-induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways. PubMed PMID: 25736991
• Sumitra M et al. Experimental myocardial necrosis in rats: Role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Molecular and Cellular Biochemistry. 2001
• Sinha M, Manna P, Sil PC. Protective effect of arjunolic acid against arsenic-induced oxidative stress in mouse brain. J Biochem Mol Toxicol. 2008;22:15-26
• Manna P et al. Protection of arsenic-induced hepatic disorder by arjunolic acid. Basic Clin Pharmacol Toxicol. 2007. [RETRACTED 2025. doi:10.1111/bcpt.70113]
• ScienceDirect Topics — Arjunolic Acid Overview
• Frontiers in Pharmacology — Natural active botanical metabolites targeting AMPK signaling for MAFLD. 2025
• A comprehensive review of the medicinal properties of Terminalia arjuna and its major constituent arjunolic acid. ScienceDirect. 2026